Panoramic Capital Partners LLC Cuts Stake in Johnson & Johnson $JNJ

Panoramic Capital Partners LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 17.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,311 shares of the company’s stock after selling 684 shares during the period. Johnson & Johnson comprises 0.4% of Panoramic Capital Partners LLC’s portfolio, making the stock its 27th largest holding. Panoramic Capital Partners LLC’s holdings in Johnson & Johnson were worth $517,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Rogco LP boosted its holdings in Johnson & Johnson by 9.4% in the 2nd quarter. Rogco LP now owns 11,938 shares of the company’s stock valued at $1,824,000 after purchasing an additional 1,026 shares in the last quarter. Impact Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 1.8% in the second quarter. Impact Capital Partners LLC now owns 23,987 shares of the company’s stock valued at $3,664,000 after buying an additional 414 shares in the last quarter. Forza Wealth Management LLC grew its holdings in Johnson & Johnson by 0.9% during the second quarter. Forza Wealth Management LLC now owns 9,604 shares of the company’s stock worth $1,467,000 after acquiring an additional 81 shares during the period. Childress Capital Advisors LLC raised its position in Johnson & Johnson by 30.9% in the second quarter. Childress Capital Advisors LLC now owns 13,004 shares of the company’s stock worth $1,986,000 after acquiring an additional 3,072 shares in the last quarter. Finally, PFG Investments LLC lifted its holdings in Johnson & Johnson by 2.8% in the second quarter. PFG Investments LLC now owns 105,492 shares of the company’s stock valued at $16,114,000 after acquiring an additional 2,879 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Bank of America boosted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Thursday, July 17th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada boosted their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $185.98 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $447.91 billion, a PE ratio of 19.89, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40. The company has a 50-day simple moving average of $175.78 and a 200-day simple moving average of $162.66. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $186.59.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.